On February 7, 2024 Regen Biopharma, Inc. filed a provisional patent application with the United States Patent and Trademark Office covering compositions of matter, protocols and treatment means for accelerating hematopoietic reconstitution after an insult or chronic pathology by administration of stem cell derived endothelial progenitor cells or endothelial cells.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7 USD | -5.41% | +2.94% | -26.32% |
1st Jan change | Capi. | |
---|---|---|
-26.32% | 2.92M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- RGBP Stock
- News Regen BioPharma, Inc.
- Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells